Last reviewed · How we verify
Hexapen (Mecillinam)
Hexapen works by inhibiting bacterial cell wall synthesis, preventing the bacteria from producing a strong cell wall.
Hexapen (Mecillinam) is a small molecule antibiotic developed by Roche, targeting an unknown mechanism. It belongs to the mecillinam class and is used to treat bacterial infections. The commercial status of Hexapen is unclear, and it is not known if it is patented or available as a generic. Key safety considerations include its short half-life of 1.1 hours and low bioavailability of 5%. Further research is needed to determine its approved indications and off-patent status.
At a glance
| Generic name | Mecillinam |
|---|---|
| Also known as | Selexid, Penomax |
| Sponsor | Roche |
| Drug class | mecillinam |
| Target | Penicillin-binding protein 2 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Mechanism of action
Imagine the bacterial cell wall as a strong brick wall. Hexapen blocks the enzymes that help build this wall, making it weak and unable to protect the bacteria. This ultimately leads to the death of the bacteria.
Approved indications
Common side effects
Key clinical trials
- Prediction and Prevention of Bloodstream Infections After Kidney Transplantation (PHASE2)
- Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care (PHASE4)
- Clinical Effectiveness and Bacteriological Eradication of 4 Short-course Antibiotics for Uncomplicated UTIs in Women. (PHASE4)
- Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis (PHASE4)
- Clinical Trial of Pivmecillinam Hydrochloride Tablets in the Treatment of Uncomplicated Urinary Tract Infection (PHASE3)
- Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in ESBL UTIs (PHASE3)
- Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy. (PHASE4)
- Treating Pyelonephritis an Urosepsis With Pivmecillinam (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hexapen CI brief — competitive landscape report
- Hexapen updates RSS · CI watch RSS
- Roche portfolio CI